Skip to main content
Premium Trial:

Request an Annual Quote

Top 10 Articles on GenomeWeb in 2017: Supreme Court Ruling; FDA Guidelines for Precision Med; More

NEW YORK (GenomeWeb) – What were the articles that gained the most interest from GenomeWeb readers this past year? The list is a cross-section of our coverage including a US Supreme Court decision, FDA guidelines, coverage of the JP Morgan Healthcare Conference, a notable acquisition, and a study of circulating tumor DNA for detecting early cancers, among others.

 Here are the top 10:

1)    Supreme Court Rules in Favor of Life Technologies in DNA Kit Component Case

2)    JPM Healthcare Day Two: 10x Genomics, Foundation Med, Quidel, Hologic, LabCorp, Nanostring, Bio-Rad

3)    FDA Releases Draft Guidelines to Clarify Regulatory Framework Supporting Precision Medicine

4)    Thermo Fisher Next-Gen Sequencing Panel Wins FDA Approval as Companion Test

5)    Illumina Launches NextSeq 550Dx, Expands Use of MiSeqDx

6)    Bio-Rad to Acquire RainDance Technologies

7)    Illumina Unveils New High-Throughput Sequencing Instrument at JP Morgan

8)    Counsyl Lays Off Oncology Sales Team

9)    FDA's Personalized Medicine Leader Leaving for Liquid Biopsy Startup Grail

10)  Sequencing of Circulating Tumor DNA Detects Early Cancers

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.